Project Grant R01CA313899
Award Date 9/1/26
Completion Date 8/31/31
Dollars Obligated $128K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Charleston, SC 29425, USA
Similar Awards
- The National Institute on Deafness and Other Communication Disorders awarded The Washington University $647,082 on August 24, 2026, under the Research Related to Deafness and Communication Disorders program (CFDA 93.173) to investigate mechanisms of hair cell vulnerability following sublethal cisplatin exposure. The research examines how cisplatin, a widely used cancer treatment, causes permanent hearing loss in patients years after treatment ends and sensitizes the cochlea to subsequent noise...
- The National Cancer Institute awarded Virginia Commonwealth University $399,187 under the Cancer Treatment Research program (CFDA 93.395) on May 7, 2026, to develop glycosaminoglycans-based theragnostic approaches for treating platinum-resistant gynecological malignancies, specifically ovarian cancer. The project supports exploratory and developmental research on how sulfated glycosaminoglycans, including heparan sulfate and chondroitin sulfate, mediate tumor uptake of platinum-based...
- The National Cancer Institute awarded The Trustees of Columbia University in the City of New York $681,818 on June 2, 2026, under the Cancer Treatment Research program (CFDA 93.395) to conduct research into restoring anti-tumor immunity in chromosomally unstable tumors. The research addresses chromosomal instability (CIN)—frequent chromosome missegregation during mitosis—as a genomic hallmark of solid tumors that correlates with immune evasion and resistance to immunotherapies. The project...
- The National Cancer Institute, a component of the Department of Health and Human Services National Institutes of Health, awarded $616,624 to The Medical University of South Carolina on May 18, 2026, under the Cancer Biology Research program (CFDA 93.396) to investigate molecular mechanisms underlying renal cell carcinoma sensitivity to BCL-XL inhibition in SETD2-deficient tumors. The project explores how loss of SETD2, a histone methyltransferase frequently mutated in renal cell carcinoma,...
- The National Cancer Institute awarded The Methodist Hospital Research Institute $415,257 on July 1, 2026, under the Cancer Treatment Research program (CFDA 93.395) to develop platinum-based nanotherapeutics for chemoresistant high-grade serous ovarian cancer. The award funds research into CARRIER-PT, a platinum nanoparticle therapy designed to overcome treatment resistance in ovarian cancer patients who fail conventional chemotherapy and immunotherapy. The work aims to determine how CARRIER-PT...
- The National Cancer Institute awarded The Medical University of South Carolina $205,788 on September 10, 2025, under the Cancer Research Manpower program (CFDA 93.398) to conduct research on peroxisome biogenesis in anti-tumor T cell metabolic fitness. The research investigates how peroxisomes—organelles that regulate fatty acids and reactive oxygen species—influence T cell exhaustion and dysfunction within the immunosuppressive tumor microenvironment. The study is motivated by preliminary...
- The National Cancer Institute awarded Beth Israel Deaconess Medical Center $444,569 on September 3, 2026, under the Cancer Treatment Research program (CFDA 93.395) to investigate cuproptosis—a copper-dependent form of regulated cell death—as a therapeutic pathway against chemoresistant high-grade serous ovarian cancer (HGSOC). The research addresses HGSOC's clinical challenge: most patients relapse after platinum-based chemotherapy, and recurrent disease develops resistance through adaptive,...
- The National Cancer Institute awarded the University of Rochester $814,967 on September 1, 2026, under the Cancer Treatment Research program (CFDA 93.395) to investigate trajectories of neurotoxicity among adolescents and young adults with Hodgkin lymphoma. The award funds research examining long-term neurotoxic effects of cancer therapy—including cancer-related cognitive impairment and peripheral and autonomic neuropathy—in this population despite the absence of central nervous...
- The National Cancer Institute awarded The Regents of the University of California, San Francisco $680,600 on August 1, 2026, under the Cancer Treatment Research program (CFDA 93.395) to overcome medulloblastoma resistance to treatment using in vivo perturb-seq and preclinical therapeutics. The project applies perturb-seq, a functional genomic technique combining pooled CRISPR interference screens with single-cell transcriptomics, to link genetic perturbations to transcriptional phenotypes in...
- The National Institutes of Health National Cancer Institute awarded the University of Southern California $479,234 on May 15, 2026, under the Cancer Biology Research program (CFDA 93.396) to investigate nonsense-mediated mRNA decay mechanisms in cancer biology. The project explores how nonsense-mediated mRNA decay (NMD) functions beyond its conventional role of degrading faulty transcripts, with three specific aims: decode gene dependencies in cancer cell lines using NMD residual signatures from...